CN105462997A - New urease prosthetic group gene and application thereof - Google Patents
New urease prosthetic group gene and application thereof Download PDFInfo
- Publication number
- CN105462997A CN105462997A CN201510977261.3A CN201510977261A CN105462997A CN 105462997 A CN105462997 A CN 105462997A CN 201510977261 A CN201510977261 A CN 201510977261A CN 105462997 A CN105462997 A CN 105462997A
- Authority
- CN
- China
- Prior art keywords
- urase
- inclusion body
- gene
- urease
- prothetic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01005—Urease (3.5.1.5)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a new urease prosthetic group gene and the application thereof. The sequence of the new urease prosthetic group gene is shown in SEQ ID No.1; after the prosthetic group provided by the invention is used, the activity of urease is obviously improved. After being renatured by the renaturation scheme, a recombinant urease inclusion body has higher specific enzyme activity compared with recombinant urease which only contains structural subunit. Furthermore, the recombinant urease inclusion body also has bifunctional enzyme properties the same as those of acid urease extracted from original bacteria. The new urease prosthetic group gene has the enzyme activity of the urease and the enzyme activity of urethane degrading enzyme, thus being wide in application prospect.
Description
Technical field
The present invention relates to a kind of prothetic group new gene and application thereof, belong to technical field of bioengineering.
Background technology
The research of the eighties, confirm in alcoholic beverage containing carcinogens matter urethanum (EC), this thing is mainly derived from alcoholic beverage to be brewageed, decocts in wine and storage process, and in alcoholic beverage, contained urea and ethanol are formed with the chemical reaction of non-enzymatic catalysis.It is reported that in fermented wine, add a small amount of acid urease can effectively remove urea in wine, and then control carcinogenic substance ethyl carbamate content.
Recombinant acid urase constructed by this laboratory has and derives from Providence bacterium JN-B815 and produce the identical bifunctional enzyme character of acid urease, can decomposing urea, also can finally generate ammonia G&W using EC as substrate simultaneously.
At present, the state investigators such as Japan, the U.S. not only screen the microbial strains of urea in decomposing alcohol beverage, have studied the enzymatic property of urase and the condition of application, and existing commercial urase drops into application.And in the yellow rice wine of China's export urase used all from external import, the domestic industrial scale that not yet formed, and the world is also less about the report of urethanum degrading enzyme.Therefore study the acid urease that acid urease for wine particularly has a urethanum degrading enzymatic activity simultaneously, to China's wine-making industry quality-improving, there is far reaching significance.
Summary of the invention
First object of the present invention provides a kind of new urase prothetic group gene nucleotide series as shown in SEQIDNO.1.
Genetic engineering bacterium containing described urease gene, expression vector or cloning vector all belong to the scope of protection of present invention.
Second object that the present invention will solve is to provide a kind of method improving urease activity, relates generally to described urase prothetic group gene and is improving application, described prothetic group gene and urase functional gene coexpression in urease activity.
Described coexpression is expressed respectively for adopting separate promoters, and concrete grammar obtains a kind of genetic engineering bacterium for urase prothetic group gene described in claim 1 and urase structure gene being imported in E.coliBL21 in the mode that double-promoter is expressed.
Described Providence bacterium JN-B815, by this laboratory screening, is preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center, deposit number: CGMCCNo.8326.
3rd object of the present invention is to provide the method for restructuring E.coliBL21 (DE3) abduction delivering full subunit acid urease inclusion body.
4th object of the present invention is to provide a kind of refolding method of high-purity urease inclusion body.
Described a kind of intracellular expression derives from the construction process of the restructuring E.coliBL21 (DE3) of Providence bacterium JN-B815 acid urease, is the acid urease structure gene ureABC and urase prothetic group gene ureEFGD substep that derive from Providence bacterium JN-B815 to be imported in E.coliBL21 (DE3) to obtain genetic engineering bacterium.Utilize the recombinant acid urase inclusion body of engineering bacterium fermentation preparation containing full subunit built, and purifying and renaturation are carried out to acid urease inclusion body.
Cloning process can adopt chemical synthesis or PCR method, and this experiment for PCR method, but is not limited to PCR method, and concrete steps are:
(1) with acid urease structural gene sequence design pair of primers Fs, Rs (sequence is respectively as shown in SEQIDNO.3, SEQIDNO.4), with Providence bacterium JN-B815 genome for template amplification goes out goal gene ureABC:
Fs：CCG
GAATTCATGCAATTAACCCCAAGGGAAATTGAA(EcoRⅠ)；
Rs：ACGC
GTCGACTTAACCAAAGAAATAACGTTGGTTCAT(SalⅠ)；
Underscore represents restriction enzyme site base sequence.
(2) goal gene ureABC is connected on pET-28a carrier, obtain recombinant vectors 1., Transformed E .coliJM109 coats containing on the LB solid plate containing that resistance of card, cultivate 12h, picking positive transformant is inoculated in the LB liquid nutrient medium containing kantlex and cultivates 12h, extract plasmid, carry out double digestion checking.Verify that correct recombinant vectors is sent to the raw work in Shanghai and checks order.
(3) the correct recombinant vectors that checks order contains in-20 DEG C of refrigerators, and called after recombinant vectors 1..
(4) recombinant vectors is built 2. with same method described in step (1) (2) (3), primer replaces with Fa, Ra (sequence is respectively as shown in SEQIDNO.5, SEQIDNO.6), and amplifying goal gene sequence is ureEFGD:
Fa：AAGGAAAAAA
GCGGCCGCTACTGTGACACAACCAGTAATT(NotⅠ)；
Ra：CC
CTCGAGTTAGCAAAATAACATTGCCAAACGTA(XhoⅠ)。
(5) with recombinant vectors 2. primers Ft, Rt, amplify recombinant vectors and 2. go up T7 promotor to ureEFGD sequence.And utilize the structure of same method described in step (1) (2) (3) to contain the recombinant vectors of double-promoter and acid urease full genome 3..
(6) by recombinant vectors 3. Transformed E .coliBL21 (DE3), restructuring E.coliBL21 (DE3) is obtained.And be inoculated in the LB of 50mL with the inoculum size of 1%, wherein containing kantlex 50 μ g/mL, NiSO
40.05g/L, urea 1%, 37 DEG C, 200rpm is cultured to OD
600between value 0.8 ~ 1.0, add IPTG to final concentration 0.5mM, 25 DEG C, 200rpm cultivates 10h.
(7) by the centrifugal 10min of gained fermented liquid 10000rpm, abandon supernatant, the PBS damping fluid Eddy diffusion of cell precipitation 10mL25mMpH7.0, after ultrasonication, centrifugal collecting precipitation, obtains urase just inclusion body.
(8) urase inclusion body Buffer I is washed once, wash twice with Buffer II.
(9) dissolved by the Buffer III of the inclusion body after washing containing 8M urea, the centrifugal supernatant that stays obtains inclusion body solution.
(10) gained inclusion body affinity chromatography in step (9) is carried out purifying.Mobile phase A is the Buffer III containing 20mM imidazoles and 8M urea, and Mobile phase B is the Buffer III containing 500mM imidazoles and 8M urea.
(11) the inclusion body solution in step (10) is loaded in dialysis tubing, and dialysis tubing is placed in Buffer III dialysis that urea concentration is 8M-0M change.Dialysis time is 6h, and dialysis temperature is 4 DEG C.
Described acid urease gene source is cloned in extracting genome to this laboratory screening bacterial strain Providence bacterium JN-B815.Acid urease structure gene as shown in SEQIDNO.2 and prothetic group gene as shown in SEQIDNO.1.
Described expression strain is E. coli BL21 (DE3).
Obtain the thick inclusion body of full subunit acid urease and wash through Buffer I, Buffer II, and affinity chromatography carries out separation and purification, obtains electrophoretically pure acid urease inclusion body.
Gained soluble acid urase after inclusion body purification renaturation, embodies the bifunctional enzyme identical with protoenzyme active.And urase is more consistent than keeping protoenzyme with EC degrading enzymatic activity, is about 3:1.This restructuring urase bifunctional enzyme is active is respectively urase 10.8U/mg more alive than enzyme all higher than the restructuring urase only containing Structural subunits, and urethanum degrading enzyme is more alive than enzyme is 3.4U/mg.Urase enzyme is lived and urethanum degradation enzyme activity is all surveyed under pH is the buffer conditions of 4.5.
Enzyme activity determination method: adopt indophenol blue reaction (Berthelotreaction) colorimetry
Enzyme is lived and is defined: at normal pressure, 37 DEG C, and under pH4.5 condition, it is 1 enzyme activity unit that per minute decomposition substrate urea or urethanum produce 1 μm of ol ammonia.Wherein, the mensuration of urea degrading enzymatic and urethanum degrading enzyme vigor adopts urea and urethanum as substrate respectively.
The enzyme that urase prothetic group gene provided by the invention can significantly improve urase is lived, and has good application prospect.In addition, the present invention devises a kind of suitable method and carries out renaturation to urase inclusion body.Confirm that this acid urease has urethanum degrading enzymatic activity simultaneously, for the application of acid urease in inebriant provides excellent basis.
Embodiment
LB (g/L): Tryptones 10, yeast extract paste 5, NaCl10, pH7.0;
BufferⅠ：50mMPBS，1mMEDTA，pH7.0；
BufferⅡ：50mMPBS，1mMEDTA，50mMNaCl，0.3％TritonX-100，pH7.0；
Buffer III: 25mMPBS, 1mMEDTA, 0.2mMGSSG, 2mMGSH, 20% glycerine, 1% glycine
E. coli JM109 (DE3), E.coliBL21 (DE3) and pET-28a carrier are by this research department's preservation
T4DNA ligase enzyme, restriction enzyme EcoR I, Sal I, Not I, Xho I and shared Buffer, agarose gel electrophoresis Marker are all purchased from precious biotechnology (Dalian) company limited.
Embodiment 1 recombinant vectors 1. construction process.
For realizing the expression of acid urease gene in intestinal bacteria, design one pair of genes primer with acid urea peptase structure gene ureABC.
Fs：CCG
GAATTCATGCAATTAACCCCAAGGGAAATTGAA(EcoRⅠ)；
Rs：ACGC
GTCGACTTAACCAAAGAAATAACGTTGGTTCAT(SalⅠ)；
Underscore represents restriction enzyme site base sequence.
With Providence bacterium genome for template, Fs and Rs is primer amplification goal gene.PCR system is (50 μ L): PrimerSTAR enzyme 25 μ L; Genome 1 μ L; Fs1 μ L; Rs1 μ L; ddH
2o22 μ L.PCR condition is: 95 DEG C of denaturation 10min; 95 DEG C of sex change 15s, 59 DEG C of annealing 30s, 72 DEG C extend 3min; 10min is extended after 72 DEG C; 35 circulations.
The goal gene that amplification is obtained and plasmid pET-28a EcoRI and Sal I single endonuclease digestion respectively, single endonuclease digestion system is as follows:
Double digestion system (40 μ L) system: goal gene/plasmid 12 μ L, restriction enzyme 2 μ L, distilled water 22 μ L, Buffer4 μ L.37 DEG C, EcoRI and Sal I endonuclease reaction 6h, glue reclaims object band.
Goal gene after double digestion is mixed with the ratio of carrier by 8:1,16 DEG C of connection also Transformed E .coliJM109 that spend the night.Coat in the LB substratum containing ammonia benzyl resistance (100 μ g/mL) and cultivate 12-16h.Picking list bacterium colony carries out the amplification of LB shake-flask culture and double digestion checking, verifies correct to carry out sequencing, checks order correct to be recombinant vectors 1..
The making of competent escherichia coli cell:
(1) the mono-colony inoculation of picking E.coliJM109 spends the night to 5mLLB Tube propagation, 37 DEG C, 200rpm (10h);
(2) receive in 50mLLB triangle shaking flask with 1% inoculum size, 37C cultivates 2-3h, to OD
600reach about 0.5;
(3) gone to by thalline aseptic, ice-cold 50mL centrifuge tube, places 10min on ice, and culture is cooled, and 4 DEG C, the centrifugal 10min of 4000rpm, abandon supernatant, pipe is inverted 1min, nutrient solution is flow to end, and collects somatic cells;
(4) with the CaCl of the 0.1mol/L of 10mL precooling
2suspension cell, places 30min on ice;
(5) 4 DEG C, the centrifugal 10min of 4000rpm, abandon supernatant, and what add 4mL precooling contains 0.1mol/LCaCl
220% glycerine solution, suspension cell, places on ice;
(6) divided by competent cell and be filled in aseptic 2mL centrifuge tube, often pipe 200ul, is stored in-80 DEG C of refrigerators.
Embodiment 2 recombinant vectors construction process is 2. as example 1
Fa：AAGGAAAAAA
GCGGCCGCTACTGTGACACAACCAGTAATT(NotⅠ)；
Ra：CC
CTCGAGTTAGCAAAATAACATTGCCAAACGTA(XhoⅠ)。
Embodiment 4 recombinant vectors construction process 3..
With the recombinant vectors built in example 2 2. for template, design primers F t, Rt amplify T7 promotor and ureEFGD sequence.1. goal gene Ft, Rt amplified with the method in example 1 is connected with the carrier built in example 1, builds recombinant vectors 3..And will successfully construct recombinant vectors 3. proceed to E.coliBL21 (DE3) obtain restructuring E.coliBL21 (DE3), (sequence is respectively as shown in SEQIDNO.7, SEQIDNO.8).
Ft：CCG
CTCGAGTAATACGACTCACTA(XhoⅠ)；
Rt：CCG
CTCGAGTTAGCAAAATAACAT(XhoⅠ)。
Embodiment 4 is recombinated the method for E.coliBL21 (DE3) abduction delivering acid urease inclusion body
More than picking recombinate E.coliBL21 (DE3), and be inoculated in the LB of 50mL with the inoculum size of 1%, wherein containing kantlex 50 μ g/mL, NiSO
40.05g/L, urea 1%, 37 DEG C, 200rpm is cultured to OD
600between value 0.8 ~ 1.0, add IPTG to final concentration 0.5mM, 25 DEG C, 200rpm cultivates 10h.By the centrifugal 10min of gained fermented liquid 10000rpm, abandon supernatant, the PBS damping fluid Eddy diffusion of cell precipitation 10mL25mMpH7.0, after ultrasonication, centrifugal collecting precipitation, obtains urase just inclusion body.Urase inclusion body Buffer I is washed once, washes twice with Buffer II.Dissolved by the Buffer III of inclusion body after washing containing 8M urea, the centrifugal supernatant that stays obtains inclusion body solution.
The purification process of embodiment 5 acid urease inclusion body
The nickel post that the inclusion body solution upper step obtained is 30mL through column volume carries out affinitive layer purification.Mobile phase A is the Buffer III containing 20mM imidazoles 8M urea, and Mobile phase B is the Buffer III containing 500mM imidazoles 8M urea, and flow velocity is 0.5mL/min.It is pure that final acquisition inclusion body reaches electrophoresis through SDS-PAGE checking.
The refolding method of embodiment 6 acid urease inclusion body
By the inclusion body solution after upper step purifying, be loaded in dialysis tubing.And dialysis tubing to be placed in urea concentration be that the Buffer III of 8M-0M change dialyses, during dialysis, carry out gentle agitation with rotor.In each Buffer III, urea concentration is changed to 1M, and the dialysis time of often kind of damping fluid is 6h, and dialysis temperature is 4 DEG C.By inclusion body solution 1000rpm after having dialysed, 4 DEG C of centrifugal 3min, collect supernatant, be the recombinant acid urase simultaneously with urethanum degrading enzymatic activity, urase specific activity has been 10.8U/mg, and urethanum degrading enzyme specific activity is 3.4U/mg.21% is reached by this step gained acid urease renaturing inclusion bodies rate.The ratio enzyme of urase and urethanum degrading enzyme is lived and is all improved 5 times than the enzyme of expression of structural gene.
Table 1 acid urease renaturing inclusion bodies result
Embodiment 7 single expression acid urease structure gene
1 construction of recombinant vector
Obtain urase structure gene ureABC by chemical synthesis or PCR cloning, the present invention is introduced for PCR cloning.
For realizing the expression of acid urease gene in intestinal bacteria, design one pair of genes primer with acid urea peptase structure gene ureABC.
Fs：CCG
GAATTCATGCAATTAACCCCAAGGGAAATTGAA(EcoRⅠ)；
Rs：ACGC
GTCGACTTAACCAAAGAAATAACGTTGGTTCAT(SalⅠ)；
Underscore represents restriction enzyme site base sequence.
With Providence bacterium genome for template, Fs and Rs is primer amplification goal gene.PCR system is (50 μ L): PrimerSTAR enzyme 25 μ L; Genome 1 μ L; Fs1 μ L; Rs1 μ L; ddH
2o22 μ L.PCR condition is: 95 DEG C of denaturation 10min; 95 DEG C of sex change 15s, 59 DEG C of annealing 30s, 72 DEG C extend 3min; 10min is extended after 72 DEG C; 35 circulations.
The goal gene that amplification is obtained and plasmid pET-28a EcoRI and Sal I single endonuclease digestion respectively, single endonuclease digestion system is as follows:
Double digestion system (40 μ L) system: goal gene/plasmid 12 μ L, restriction enzyme 2 μ L, distilled water 22 μ L, Buffer4 μ L.37 DEG C, EcoRI and Sal I endonuclease reaction 6h, glue reclaims object band.
Goal gene after double digestion is mixed with the ratio of carrier by 8:1,16 DEG C of connection also Transformed E .coliJM109 that spend the night.Coat in the LB substratum containing ammonia benzyl resistance (100 μ g/mL) and cultivate 12-16h.Picking list bacterium colony carries out the amplification of LB shake-flask culture and double digestion checking, verifies correct to carry out sequencing, checks order correct to be recombinant vectors.
The making of competent escherichia coli cell:
(1) the mono-colony inoculation of picking E.coliJM109 spends the night to 5mLLB Tube propagation, 37 DEG C, 200rpm (10h);
(2) receive in 50mLLB triangle shaking flask with 1% inoculum size, cultivate 2-3h, to OD for 37 DEG C
600reach about 0.5;
(3) gone to by thalline aseptic, ice-cold 50mL centrifuge tube, places 10min on ice, and culture is cooled, and 4 DEG C, the centrifugal 10min of 4000rpm, abandon supernatant, pipe is inverted 1min, nutrient solution is flow to end, and collects somatic cells;
(4) with the CaCl of the 0.1mol/L of 10mL precooling
2suspension cell, places 30min on ice;
(5) 4 DEG C, the centrifugal 10min of 4000rpm, abandon supernatant, and what add 4mL precooling contains 0.1mol/LCaCl
220% glycerine solution, suspension cell, places on ice;
(6) divided by competent cell and be filled in aseptic 2mL centrifuge tube, often pipe 200ul, is stored in-80 DEG C of refrigerators.
And will successfully construct recombinant vectors proceed to E.coliBL21 (DE3) obtain restructuring E.coliBL21 (DE3).
More than 2 restructuring E.coliBL21 (DE3) abduction delivering soluble acid urase pickings recombinate E.coliBL21 (DE3), and be inoculated in the LB of 50mL with the inoculum size of 1%, wherein containing kantlex 50 μ g/mL, NiSO
40.05g/L, 37 DEG C, 200rpm is cultured to OD
600between value 0.8 ~ 1.0, add IPTG to final concentration 0.5mM, 25 DEG C, 200rpm cultivates 10h.By the centrifugal 10min of gained fermented liquid 10000rpm, abandon supernatant, the citrate buffer solution Eddy diffusion of cell precipitation 10mL25mMpH4.5, after ultrasonication, collected by centrifugation supernatant, obtains urase just enzyme liquid.
Upper step is obtained urase crude enzyme liquid and is placed in neutral PBS damping fluid and dialyses 24h by the purifying of 3 acid ureases.The nickel post being 30mL through column volume carries out affinitive layer purification.Mobile phase A is for containing 20mM imidazoles PBS, and Mobile phase B is the PBS containing 500mM, and flow velocity is 0.5mL/min.It is pure that final acquisition urase reaches electrophoresis through SDS-PAGE checking.Purified gained soluble acid urase, embodies the bifunctional enzyme identical with protoenzyme active.And urase is more consistent than keeping protoenzyme with EC degrading enzymatic activity, is about 3:1.Urase is more alive than enzyme is 2.1U/mg, and urethanum degrading enzyme is more alive than enzyme is 0.6U/mg.
Claims (8)
1. a new urase prothetic group gene, is characterized in that nucleotide sequence is as shown in SEQIDNO.1.
2. the genetic engineering bacterium containing urase prothetic group gene described in claim 1.
3. the expression vector containing urase prothetic group gene described in claim 1 or cloning vector.
4. urase prothetic group gene described in claim 1 is improving the application in urease activity, it is characterized in that prothetic group gene described in claim 1 and urase structure gene coexpression.
5. method according to claim 4, is characterized in that described coexpression is expressed respectively for adopting separate promoters.
6. the method described in claim 4 or 5, is characterized in that urase prothetic group gene described in claim 1 and urase structure gene to import in E.coliBL21 in the mode that double-promoter is expressed to obtain a kind of genetic engineering bacterium; Step is:
(1) clone on urase structure gene ureABC to expression vector pET-28a, obtain recombinant plasmid pET-28a-ureABC;
(2) clone urase prothetic group gene ureEFGD to expression vector pET-28a, obtain recombinant plasmid pET-28a-ureEFGD;
(3) by step 2) in urase prothetic group gene on constructed recombinant plasmid pET-28a-ureEFGD and T7 promoter sequence clone together, and steps for importing 1) described in recombinant plasmid pET-28a-ureABC, build new recombinant plasmid pET-28a-ureABC-ureEFGD;
(4) by recombinant plasmid pET-28a-ureABC-ureEFGD Transformed E .coliBL21 (DE3) correct for order-checking, restructuring E.coliBL21 (DE3) is obtained.
7. prepare a method for high reactivity urase, it is characterized in that comprising the steps:
(1) by after restructuring E.coliBL21 (DE3) the activation inoculation described in claim 6, OD is cultured to
600between value 0.8 ~ 1.0, add IPTG induction;
(2) by gained fermented liquid high speed centrifugation, the neutral PBS damping fluid Eddy diffusion of cell precipitation, after ultrasonication, centrifugal collecting precipitation, obtains urase just inclusion body;
(3) urase inclusion body Buffer I is washed once, wash twice with Buffer II;
(4) dissolved by the Buffer III of the inclusion body after washing containing 8M urea, the centrifugal supernatant that stays obtains inclusion body solution;
(5) by step 4) the inclusion body solution affinity chromatography that obtains carries out purifying; Inclusion body solution after purifying is placed in urea concentration and carries out dialysis renaturation by the Buffer III of 8M to 0M.
8. method according to claim 7, is characterized in that described urase structure gene ureABC sequence is as shown in SEQIDNO.2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510977261.3A CN105462997A (en) | 2015-12-23 | 2015-12-23 | New urease prosthetic group gene and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510977261.3A CN105462997A (en) | 2015-12-23 | 2015-12-23 | New urease prosthetic group gene and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105462997A true CN105462997A (en) | 2016-04-06 |
Family
ID=55601156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510977261.3A Pending CN105462997A (en) | 2015-12-23 | 2015-12-23 | New urease prosthetic group gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105462997A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111254135A (en) * | 2020-03-03 | 2020-06-09 | 江南大学 | Urease mutant with improved application performance |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905923A (en) * | 1974-04-04 | 1975-09-16 | Minnesota Mining & Mfg | Poly (urea-urethane) foams containing immobilized active enzymes |
| CN1955282A (en) * | 2006-10-12 | 2007-05-02 | 江南大学 | Preparation method and application of fermentation producing wine acid urase using intestinal bacillus |
| CN101062015A (en) * | 2007-05-22 | 2007-10-31 | 中国药科大学 | Urease epitope fusion peptide liposome bacterin for preventing the helicobacter pylori infecting |
| CN102242109A (en) * | 2011-04-29 | 2011-11-16 | 江南大学 | Method for keeping stability of immobilized acid urease membrane |
| CN102676399A (en) * | 2012-04-26 | 2012-09-19 | 江南大学 | Ethyl carbamate (EC) catabolic enzyme generating bacterium for yellow wine |
| CN103127498A (en) * | 2011-12-02 | 2013-06-05 | 上海联合赛尔生物工程有限公司 | Recombination antigen composition, vaccine and carrier and method for preparing antigen composition |
| CN103923900A (en) * | 2014-04-14 | 2014-07-16 | 江南大学 | Preparation method and application of cross-linked enzyme aggregate of bifunctional enzyme for rice wine |
| CN103937714A (en) * | 2014-04-14 | 2014-07-23 | 江南大学 | Bacterial strain producing acid urease and EC degrading enzyme and application of bacterial strain |
| CN103990121A (en) * | 2013-12-06 | 2014-08-20 | 上海联合赛尔生物工程有限公司 | Antigen chimera, antigen composition, vaccine and preparation method and kit thereof |
| CN104962541A (en) * | 2015-03-31 | 2015-10-07 | 芜湖康卫生物科技有限公司 | Purifying process for oral recombinant helicobacter pylori vaccine |
-
2015
- 2015-12-23 CN CN201510977261.3A patent/CN105462997A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905923A (en) * | 1974-04-04 | 1975-09-16 | Minnesota Mining & Mfg | Poly (urea-urethane) foams containing immobilized active enzymes |
| CN1955282A (en) * | 2006-10-12 | 2007-05-02 | 江南大学 | Preparation method and application of fermentation producing wine acid urase using intestinal bacillus |
| CN101062015A (en) * | 2007-05-22 | 2007-10-31 | 中国药科大学 | Urease epitope fusion peptide liposome bacterin for preventing the helicobacter pylori infecting |
| CN102242109A (en) * | 2011-04-29 | 2011-11-16 | 江南大学 | Method for keeping stability of immobilized acid urease membrane |
| CN103127498A (en) * | 2011-12-02 | 2013-06-05 | 上海联合赛尔生物工程有限公司 | Recombination antigen composition, vaccine and carrier and method for preparing antigen composition |
| CN102676399A (en) * | 2012-04-26 | 2012-09-19 | 江南大学 | Ethyl carbamate (EC) catabolic enzyme generating bacterium for yellow wine |
| CN103990121A (en) * | 2013-12-06 | 2014-08-20 | 上海联合赛尔生物工程有限公司 | Antigen chimera, antigen composition, vaccine and preparation method and kit thereof |
| CN103923900A (en) * | 2014-04-14 | 2014-07-16 | 江南大学 | Preparation method and application of cross-linked enzyme aggregate of bifunctional enzyme for rice wine |
| CN103937714A (en) * | 2014-04-14 | 2014-07-23 | 江南大学 | Bacterial strain producing acid urease and EC degrading enzyme and application of bacterial strain |
| CN104962541A (en) * | 2015-03-31 | 2015-10-07 | 芜湖康卫生物科技有限公司 | Purifying process for oral recombinant helicobacter pylori vaccine |
Non-Patent Citations (6)
| Title |
|---|
| LU-QIANG YANG等: "Purification, Properties, and Application of a Novel Acid Urease from Enterobacter sp.", 《APPL BIOCHEM BIOTECHNOL》 * |
| QIAN ZHANG等: "Preparation of crosslinked enzyme aggregates (CLEAs) of acid urease with urethanase activity and their application", 《J. BASIC MICROBIOL.》 * |
| 杨广明: "酸性脲酶与氨基甲酸乙酯降解酶产生菌的筛选及酶的特性", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 王松华等: "产酸性脲酶菌株的筛选、鉴定及其脲酶的应用初探", 《生物技术通报》 * |
| 王玉美等: "肠杆菌酸性脲酶的提取及基本特性", 《食品工业科技》 * |
| 贡成良，曲春香主编: "《生物化学与分子生物学实验指导》", 30 June 2010 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111254135A (en) * | 2020-03-03 | 2020-06-09 | 江南大学 | Urease mutant with improved application performance |
| CN111254135B (en) * | 2020-03-03 | 2021-09-28 | 江南大学 | Urease mutant with improved application performance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102199581B (en) | Zearalenone toxin degradation enzyme and coding gene and application thereof | |
| CN102676480B (en) | Method for producing extracellular pullulanase by applying auto-induction culture medium and dual-temperature control strategy | |
| US10829755B2 (en) | Genetically engineered arginine deiminase modified by site-directed mutagenesis | |
| CN107641622A (en) | Hydrolyzable para-Phthalonitrile prepares the nitrilase of paracyanobenzoic acid | |
| CN103834629A (en) | Recombinant high-temperature pullulanase and preparation method thereof | |
| CN102660570B (en) | Method for improving thermal stability of enzyme | |
| CN105176955A (en) | Nitrilase derived from arabis alpina, gene, vector, engineering bacterium and application of nitrilase | |
| CN104962540A (en) | Nitrilase, encoding genes, carrier and application | |
| CN102226166A (en) | Gene engineering strain for efficiently expressing pullulanase and construction method thereof | |
| CN113801239B (en) | Polypeptide tag, highly soluble recombinant nitrilase and application thereof in synthesis of medicinal chemicals | |
| CN101407780B (en) | Method for preparing (R)-styrene glycol by changing coenzyme specificity and stereoselectivity via site-directed mutagenesis | |
| CN105950596B (en) | A kind of difunctional acid urease gene and its expression and application | |
| CN102898512B (en) | Recombinant plectasin as well as preparation method and application of recombinant plectasin | |
| CN105039191A (en) | Surface display method and application of trehalose synthase and trehalose-hydrolysing | |
| CN105462997A (en) | New urease prosthetic group gene and application thereof | |
| CN107151674A (en) | Novel antimicrobial peptide DLP4 preparation method | |
| CN105462998A (en) | Double-functional acidic urease structural gene as well as expression and application thereof | |
| CN103352045B (en) | Arylsulfatase and preparation method and applications thereof | |
| CN109022404A (en) | A kind of novel Cold tolerance algin catenase AlgA7 and its application | |
| CN101182475A (en) | Pichia yeast highly-effective expression of elastase as well as construction method and uses thereof | |
| CN106834328A (en) | A kind of S ribosylhomocysteines lyase gene recombinant expression carrier and its expression and application | |
| CN107267547A (en) | Novel antimicrobial peptide DLP2 preparation method | |
| CN102533808A (en) | Method for expressing and purifying recombinant ethanol oxidase in pichia pastoris | |
| CN103740659B (en) | Enzymatic thermal stability improving method | |
| CN103740661B (en) | Enzymatic thermal stability improving method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |